The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience | Zendy

Huyền Trần Thị | Zendy; Lan Phạm Thị | Zendy; Thường Nguyễn Văn | Zendy; Phương Phạm Thị Minh | Zendy; Hao Trong Nguyen | Zendy; Trở Châu Văn | Zendy; Sáu Nguyễn Hữu | Zendy; Trang Trinh Minh | Zendy; Nghi Dinh Huu | Zendy; Tâm Hoàng Văn | Zendy; Van Tran Cam | Zendy; My Le Huyen | Zendy; Khang Tran Hau | Zendy; Thuy Nguyen Thanh | Zendy; Phượng Hoàng Thị | Zendy; Linh Nguyễn Thùy | Zendy; Marco Gandolfi | Zendy; Francesca Satolli | Zendy; Claudio Feliciani | Zendy; Michael Tirant | Zendy; Aleksandra Vojvodić | Zendy; Torello Lotti | Zendy

Open Access

The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience

Author(s) -

Huyền Trần Thị,

Lan Phạm Thị,

Thường Nguyễn Văn,

Phương Phạm Thị Minh,

Hao Trong Nguyen,

Trở Châu Văn,

Sáu Nguyễn Hữu,

Trang Trinh Minh,

Nghi Dinh Huu,

Tâm Hoàng Văn,

Van Tran Cam,

My Le Huyen,

Khang Tran Hau,

Thuy Nguyen Thanh,

Phượng Hoàng Thị,

Linh Nguyễn Thùy,

Marco Gandolfi,

Francesca Satolli,

Claudio Feliciani,

Michael Tirant,

Aleksandra Vojvodić,

Torello Lotti

Publication year - 2019

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2019.069

Subject(s) - fexofenadine , levocetirizine , medicine , antihistamine , cetirizine , chronic urticaria , desloratadine , loratadine , gastroenterology , anesthesia , pharmacology

Chronic urticaria, a mast cell-driven condition, is common, debilitating and hard to treat. H1-antihistamines are the first line treatment of chronic urticaria, but often patients do not get satisfactory relief with the recommended dose. European guidelines recommend increased antihistamine doses up to four-fold.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research